APR 10, 2020 8:54 PM PDT

Cancer Therapy Drug Reverses Kidney Damage

WRITTEN BY: Nouran Amin

According to a study published in the journal Science Translational Medicine, a therapeutic previously used for cancer therapy has shown promising effects on reversing kidney damage in patients with systemic lupus erythematosus (SLE, or lupus).

Learn more about SLE:

"Kidney damage affects about half of the patients with lupus, sometimes leading to renal failure with a requirement for dialysis or transplantation," said Joe Craft, the Paul B. Beeson Professor of Medicine (rheumatology) and professor of immunobiology at Yale University. "Finding what causes that damage is extremely important."

SLE is an autoimmune disease caused by the individual’s immune cells attack their own tissues and kidneys can be particularly susceptible to the disease pathology resulting in lupus nephritis.

For lupus nephritis, a cell population referred to as ‘T-cells’ colonize kidney tissue triggering a decrease in oxygen and leading to tissue damage, potentially end-stage kidney disease. When researchers investigated the effects on infiltrating T-cells, they found that the T-cells express a marker known as hypoxia-inducible factor-1 (HIF-1) that is dependent on oxygen levels in the kidney. Activating HIF-1, results in the T-cells attacking the kidney tissues and furthering causing destruction of kidney function.

These findings allowed investigators to hypothesize that inhibiting HIF-1 function might increase oxygen levels and reduce the impact on kidneys. Thus, researchers used the HIF-1 blocking drug previously utilized in cancer therapy on mouse models of lupus.

"The findings suggest this therapy might be beneficial in lupus nephritis," Craft said. "Since this drug and others that block HIF-1 function have been used in humans with cancer, they could be used for treatment of patients with lupus."

Source: Science Daily

 

About the Author
  • Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
MAY 12, 2021
Technology
Belkin Laser Completes Enrollment for Trial Studying New Glaucoma Laser Treatment
MAY 12, 2021
Belkin Laser Completes Enrollment for Trial Studying New Glaucoma Laser Treatment
Belkin Laser, a small Israel-based biotechnology company, has announced that it has completed enrollment for its pivotal ...
MAY 11, 2021
Cardiology
Red Blood Cells Could Help Predict Recovery in Cardiovascular Patients
MAY 11, 2021
Red Blood Cells Could Help Predict Recovery in Cardiovascular Patients
Cells are one of the basic building blocks of life. There are hundreds of different cell types, and they all work togeth ...
MAY 11, 2021
Genetics & Genomics
Gene Therapy Trial for Severe Immune Disorder is Successful
MAY 11, 2021
Gene Therapy Trial for Severe Immune Disorder is Successful
Severe combined immunodeficiency (SCID), which virtually eliminates a patient's immune system, and severely affects thei ...
JUN 01, 2021
Immunology
Nanoparticles Designed to Enhance Seasonal Flu Vaccines
JUN 01, 2021
Nanoparticles Designed to Enhance Seasonal Flu Vaccines
Seasonal flu vaccines only work around 40 to 60 percent of the time, says the U.S. Centers for Disease Control and Preve ...
JUN 03, 2021
Drug Discovery & Development
Antibiotics Ineffective Against Lung-Scarring Disease
JUN 03, 2021
Antibiotics Ineffective Against Lung-Scarring Disease
Researchers behind a large trial of antibiotics for chronic lung diseases have found that that the drugs are ineffective ...
JUL 27, 2021
Immunology
Rethinking Immune Responses Involved in Skin Hypersensitivity
JUL 27, 2021
Rethinking Immune Responses Involved in Skin Hypersensitivity
A study by immunologists at the University of Copenhagen has revealed a never-before-seen immune pathway invol ...
Loading Comments...